RxDoctor Payments Data

Glenn Pomerance, MD

Ophthalmology · Chattanooga, TNNPI 1609868017

Payments from drug & device makers

$3,365in general payments, 2019–2025

Across 129 payments — averaging $26.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$537
  • Bausch & Lomb Americas Inc.$451
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$295
  • Alcon$261
  • Oyster Point Pharma, Inc.$259
  • Aerie Pharmaceuticals, Inc.$251
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,365 in reported general payments places this provider in the 65th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$78,929
Medicare patients
415
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine83$92,920
RocklatanNetarsudil Mesylat/Latanoprost34$19,301
XiidraLifitegrast16$16,760
LumiganBimatoprost31$11,457
Cyclosporine27$10,157
CombiganBrimonidine Tartrate/Timolol12$6,011
RhopressaNetarsudil Mesylate16$4,768
Travoprost26$4,094
Timolol MaleateTimolol Maleate/Pf16$3,923
Latanoprost152$2,640
Prednisolone Acetate27$1,331
Brimonidine Tartrate35$1,179
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat41$829
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$791
Dorzolamide Hcl16$453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$537$110,389126 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$251$24,06950 claims
Bausch & Lomb Americas Inc.Xiidra$451$16,76016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →